ClinicalTrials.gg
RecruitingNCT06387017BIOCEPTIONUpdated Nov 10, 2026

Prospective Multicenter Cohort Study to Validate Four Groups of Biomarkers for Assessing Lung Cancer Risk Among Patients With Atheromatous Cardiovascular Disease in a Screening Pathway

An interventional study of blood sampling and stool collection in Smoking-related Pathology, Atheroma and Non-progressive Cancer > 5 Years, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 10, 2026Study contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
750
Allocation
Not applicable
Ages
45 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Plaque, Atherosclerotic with a site in France — 5 open to participants now, 7 under way, 1 of them phase 3. Plaque, Atherosclerotic · France.

Started
2024
with 1 other
No phase
4 of 10
3 open now
Registered
7th of 10
by date
Lead sponsor
2 of 10
Assistance Publique Hopitaux De Marseille

Among the 10 studies in Plaque, Atherosclerotic with a site in France, this one is one of 2 that started in 2024, is one of 4 with no phase, and was the 7th registered.

Plaque, Atherosclerotic

105 studies on the registry are indexed under Plaque, Atherosclerotic; 27 are open to participants now.

Browse Plaque, Atherosclerotic studies →

Open to participants now

5 of the 10 studies in Plaque, Atherosclerotic with a site in France are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 16 Plaque, Atherosclerotic studies recruiting now, 7 (44%) set no upper age limit and 4 (25%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.

This study: 45 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Plaque, Atherosclerotic with a site in France, or all of them as a file.
02

Study summary

Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation.

Read the detailed description

This study aims to validate candidate biomarkers associated with the risk of lung cancer diagnosis among patients with atheromatous disease associated with smoking.

hese candidate biomarkers were identified from blood and stool samples taken from the PREVALUNG cohort (NCT03976804), comprising 512 patients with at least one smoking-related atheromatous disease who underwent a thoracic CT lung cancer screening pathway (1 single screening round, i.e. one CT scan and one year of follow-up) at the Marie Lannelongue Hospital - Groupe Hospitalier Paris Saint-Joseph (Le Plessis-Robinson). This screening pathway led to the diagnosis of 14 patients (3%) with lung cancer, over 70% of whom were early-stage (I or II) and could be managed curatively by minimally invasive surgery (unpublished results, presented at the World Congress Lung cancer in Singapore on September 10 and 11, 2023). A case-control study nested in the PREVALUNG cohort compared the biological profiles of patients with suspected lung cancers or nodules with those of patients without lung nodules. Around 15,000 biomarkers per case and control were analyzed by standard statistical methods (descriptive and logistic regression), partial least square method and machine learning after reduction of the number of variables.

By analyzing several types of variables linked to inflammation, immunity, blood metabolomics and stool metagenomics, these analyses identified 14 biomarkers divided into 4 groups of candidate biomarkers associated with the diagnosis of lung cancers the second cohort, PREVALUNG ETOILE (NCT05649046), was recruited at Marseille's Hôpital Nord, using the same intervention methods as PREVALUNG, but extending the inclusion criteria to other tobacco-related diseases (atheroma, but also chronic bronchitis and tobacco-related cancers in remission for more than 5 years), to people who would have been eligible in the prospective-randomized studies that have shown that lung cancer screening reduces lung cancer mortality (NLST and NELSON), and to people meeting the criteria of the North American recommendations. The aim of the PREVALUNG ETOILE study is to set up and evaluate a lung cancer screening care pathway at the APHM, using a biological blood and faeces collection identical to that of PREVALUNG. PREVALUNG ETOILE plans to include 160 participants in 2023 (160 have already been included as of September 20, 2023). A 5-month follow-up after the first screening round is planned for each participant. The total number of participants to be included in Europe is 2750. The number of participants to be included in the French BIOCEPTION cohort will therefore be a maximum of 2,750. APHM is coordinating data collection from the various European centers involved in the PREVALUNG BIOCEPTION study. Pr Tatiana Kouznetsova of KU Leuven (Belgium) is in charge of the statistical analysis of the data, in collaboration with APHM.

The PREVALUNG BIOCEPTION cohort was set up to validate biomarkers of risk of incident lung cancer at 2 years, as part of screening. These biomarkers will subsequently serve as therapeutic targets for the primary prevention of lung cancer. As part of the PREVALUNG EU project, a prospective randomized 8-arm study is planned to demonstrate the biological effect of drug interventions on the 4 classes of biomarkers that will have been validated (see PREVALUNG EU appendix).

This protocol is therefore part of a scientifically validated project funded by the European Commission for the validation of biological biomarkers and the primary prevention of lung cancer risk in patients with smoking-related atheromatous disease. External validation of biomarkers from a cohort of participants at risk of lung cancer without atheromatous disease or moderate or severe calcium score (some participants of PREVALUNG ETOILE or newly recruited) will initiate the extension of the validation and application of these biomarkers to non-atheromatous populations.

03

Conditions studied

  • Smoking-related Pathology
  • Atheroma
  • Non-progressive Cancer > 5 Years
  • Lung Cancer
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • 1- All PREVALUNG or PREVALUNG ETOILE participants
  • 2- Active or former smokers who have smoked daily for at least 10 years and have either atheromatous disease (coronary, lower limb, supra-aortic trunk, aortic, visceral or upper limb arteries) or a moderate or high coronary calcium score*, **.

Inclusion criteria:

  • Age 45- 75 years and
  • Medical follow-up for smoking-related atheromatous pathology and
  • daily smoking for at least 10 years prior to disease (for smoking, there are no quantitative criteria or withdrawal times)

    • visual coronary calcium score quantified by a radiologist on a chest CT scan.

      3- Individuals at risk of lung cancer without atheromatous disease or moderate or high calcium score being managed for a tobacco-related disease (chronic bronchitis or non-progressive cancer > 5 years) or with eligibility criteria for lung cancer screening (inclusion criteria in the NLST or NELSON studies or American recommendations)**.

Inclusion criteria :

  • Age 45- 75 and
  • Medical follow-up for a smoking-related pathology:
  • / emphysema, or
  • history of non-progressive cancer > 5 years, including ENT, lung, breast, cervix, excreto-urinary tract, bladder, esophagus, stomach, pancreas, liver, kidney, chronic myeloid leukemia.

and

- daily smoking for at least 10 years prior to the disease (for smoking, there are no quantitative criteria or withdrawal periods).

Or

Inclusion criteria in NLST :

  • Age 55 - 74
  • Cumulative smoking ≥ 30 pack-years
  • active or weaned for less than 15 years Or

NELSON inclusion criteria :

  • Age 50-75
  • Smoking :
  • > 15 cigarettes /D for more than 25 years or
  • > 10 cigarettes /D for more than 30 years
  • active smoking or cessation \< 10 years Or

American recommendations :

  • Age 50 - 80
  • Smoking ≥20 PA

Exclusion Criteria:

  • cancer history \< 5 years (except carcinoma in situ of the uterine cervix, basal cell carcinoma of the skin, non-invasive urothelial carcinoma treated for curative purposes without CT lung surveillance, prostate cancer with unmeasurable PSA)
  • symptoms of lung cancer (involuntary weight loss > 7 kg in 1 year, hemoptysis)
  • known history of pulmonary nodule requiring specialized follow-up
  • history of pulmonary fibrosis or pulmonary hypertension
  • active pulmonary parenchymal infection
  • severe cardiac or respiratory insufficiency (rest dyspnea)
  • performance status (WHO) 2, 3 or 4
  • patient not affiliated to the social security system (beneficiary or beneficiary's beneficiary)
  • patient deprived of liberty
  • patients under guardianship or trusteeship
  • pregnant or breast-feeding women
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
750 participants (estimated)

Study arms

  • Other
    all patients

    Diagnostic Test: blood sampling · Diagnostic Test: stool collection · Radiation: low dose CT scan

Interventions

  • Diagnostic testblood sampling

    blood collection

  • Diagnostic teststool collection

    stool collection

  • Radiationlow dose CT scan

    low dose CT scan evaluation

06

What researchers measure

Primary outcomes

  1. biomarker group validation

    Sensitivity and specificity of each biomarker

    Time frame: 51 months

Secondary outcomes

  1. Describe changes in biomarkers over time

    reporting the value of each biomarker at each patient's visit to visit

    Time frame: 51 months

  2. Describe and compare biomarkers according to clinical characteristics of participants

    Value of each biomarker according to the clinical characteristics of participants

    Time frame: 51 months

  3. Describe changes in quality of life over time

    Quality of life (SF-12 score) at each visit.

    Time frame: 51 months

  4. Describe changes in smoking habits over time

    Smoking cessation rate achieved (partial and/or total) among participants active smokers

    Time frame: 51 months

  5. Describe changes in anxiety over time

    anxiety (STAI-YA and STAI-YB) at each visit.

    Time frame: 51 months

  6. Describe and compare biomarkers according to medical characteristics of participants

    Value of each biomarkers according to medical characteristics of participants

    Time frame: 51 months

  7. Describe and compare biomarkers according to geographic characteristics of participants

    Value of each biomarkers according to geographic characteristics of participants

    Time frame: 51 months

  8. Describe and compare biomarkers according to socioeconomic characteristics of participants

    Value of each biomarkers according to socioeconomic characteristics of participants

    Time frame: 51 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jul 2028, 51 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2024
First posted
Apr 26, 2024
StartActual
Apr 2, 2024
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Contact
Study contact changed: a•••@ap-hm.fr · •••1245→d•••@ap-hm.fr · •••6018; removed d•••@ap-hm.fr. See the current contact
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Contact Study contact changed: a•••@ap-hm.fr · •••1245→d•••@ap-hm.fr · •••6018; removed d•••@ap-hm.fr. See the current contact
    + 3 other changes: verification date, criteria formatting and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06387017
Responsible party
Sponsor
First posted
Apr 26, 2024
Start date
Apr 2, 2024
Primary completion
Jul 2028 (estimated)
Completion
Jul 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

David BOULATE, Pr
Contact
david.boulate@ap-hm.fr
+33491966018
David BOULATE, Pr
study director · Assistance Publique Hopitaux De Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion